In the article entitled “Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review” by O’Donnell et al., the authors report two errors. First, in Table 3, under Cilostazol’s Serious Vascular Event Risk Reduction (95% CI) column, the values should be “(0.41–0.91)” instead of “(0.41–0.01).” Second, on page 1641, the reference number of the “Efficacy” category under the “Cilostazol Versus Control” Section should be “41” instead of “42.” The authors regret these errors.

The corrected version can be viewed online at http://stroke.ahajournals.org.
Correction

*Stroke*. 2008;39:e147
doi: 10.1161/STROKEAHA.107.000006

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/39/9/e147

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/